N/A N=56 The Autonomic Nervous System and the Metabolic Syndrome
Obesity
Primary: Insulin Resistance — 3.8; 3.1 mg/kg/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=40 Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease
Parkinson's Disease
Primary: Unified Parkinson Disease Rating Scale (UPDRS). — 12; 12; 10; 10 units on a scale
N/A N=22 Hypoglycemia and Autonomic Nervous System Function
Hypoglycemia
Primary: Change in Baroreflex Sensitivity — 2.3; -1.6 ms/mmHg
N/A N=9 Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
Alzheimer Disease · Neurodegenerative Diseases
Primary: Alpha-synuclein Levels From Nasal Swabs
N/A N=51 Physiological Effects of Nutritional Support in Patients With Parkinson's Disease
Parkinson Disease · Idiopathic Parkinson Disease
Primary: Distribution Volume Ratio — 2.65; 2.70; 2.96; 2.74 Distribution volume ratios — p=0.05
N/A N=41 Neurogenic Inflammation in Diabetes
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84
Phase 2 N=33 Safety Study of Pyridostigmine in Heart Failure
Heart Failure
Primary: Baseline Heart Rate Recovery — 32.5; 30.4 beats per minute
N/A N=55 Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
Neurofibromatosis 1
Primary: Mitochondrial Respiration Efficiency (as Measured by OCR). — 67.7167; 53.7000; 73.3358; 68.5789 picomole/minute — p=<0.01
Phase 4 N=47 Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension
Hypertension
Primary: Sympathetic Nerve Activity — 46; 40; 49; 42 bursts/min
N/A N=96 Effect of a Sequence of Specific Manual Therapy Techniques Targeting the Autonomic Nervous System in Healthy Adults
Autonomic Imbalance
Primary: Change in Heart Rate — -2.40; -0.94 beat per minute
N/A N=112 Nitric Oxide and the Autonomic Nervous System
Hypertension · Pure Autonomic Failure
Primary: Change in Systolic Blood Pressure — 43; 21 mm Hg
Early Phase 1 N=76 Autonomic Neuropathy, GI Motility, and Inflammation in HIV
HIV Disease
Primary: Change in Breath Test — 28; 14 ppm
Phase 2 N=18 L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1
Hereditary Sensory and Autonomic Neuropathy Type I
Primary: Charcot Marie Tooth Neuropathy Score — 25.67; 20.22 scores on a scale
N/A N=325 PASCONAL NERVENTROPFEN in the Treatment of Nervous Diseases
Nervousness · Sleep Disorders
Primary: Sumscore of 12 Individual Symptoms for Visit 1 (Baseline), Visit 2, and Visit 3 — 15.8; 9.2; 5.1; 6.2 units on a scale
N/A N=22 Combined Brain and Peripheral Nerve Stimulation for Stroke
Stroke
Primary: Active Range of Motion of Wrist Extension in the Paretic Side — 37.8; 38; 37.2; 38 degrees
Phase 2 N=16 Neuromyelitis Optica (NMO) & Cetirizine
Neuromyelitis Optica
Primary: Annualized Relapse Rate Before Cetirizine — 0.4; 0.1 relapses per year
N/A N=15 Cancer Anorexia and the Central Nervous System
Cancer Cachexia
Primary: ACTIVATION/NON ACTIVATION OF SPECIFIC BRAIN AREAS, EVALUATED BY FUNCTIONAL MAGNETIC RESONANCE — 585.57; 667.92; 511.22 BOLD
N/A N=46 Neurologic Injuries in Adults With Urea Cycle Disorders
Brain Diseases, Metabolic, Inborn · Urea Cycle Disorder · Ornithine Transcarbamylase Deficiency
Primary: Concentration of Glutamine and Myoinositol by MRS — 4.97; 3.66; 3.78; 4.50 mM — p=0.003
N/A N=15 Neural Signatures of Parkinson's Disease
Parkinson's Disease
Primary: Change in Resting State Beta Band Power Over Time — -0.28 regression beta coefficient — p=0.038
N/A N=23 Stress and the Nervous System
Autonomic Nervous System · Baroreflex · Stress, Physiological
Primary: Cardiovagal Baroreflex Sensitivity (Modified Oxford Technique) — 17.75; 16.90; 14.42; 17.27 ms/mmHg
Early Phase 1 N=32 Premature Fatigue in Veterans With Heart Failure: Neuronal Influences
Heart Failure
Primary: Maximal Voluntary Quadriceps Force [% Change From Baseline] — -30; -5 percentage change
Phase 2 N=3 NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome
Menkes Disease · Occipital Horn Syndrome
Primary: Treatment Related Adverse Events as Assessed by CTCAE v4.0 — 10; 6 adverse events
Phase 1 N=9 Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease
Parkinson's Disease · Gaucher's Disease
Primary: Brain GSH — 55; 41; 34 percent increase from baseline
Phase 2 N=45 The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome · Chronic Fatigue Syndrome · Myalgic Encephalomyelitis
Primary: Change in Peak Oxygen Uptake (Peak VO2) Between the First and Second iCPET — 13.3; -40.3; 111.8 mL/min — p=0.043
N/A N=30 Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders
Conversion Disorder
Primary: Gray Matter Volume Biomarkers of 6 Month Prognosis as Measured by Voxel Based Morphometry - Within Group Comparison — 4.18; 3.27; 3.85; 3.76 peak voxel z-score
N/A N=30 The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease
Parkinson's Disease With Dementia
Primary: Change in Unified Parkinson's Disease Rating Scale (UPDRS) From Baseline to 8 Weeks. — 71.6; 66.7; 67.9; 65.2 Scores on a scale
N/A N=7 Study to Investigate the Ability of [11C]Donepezil PET to Image the Parasympathetic Nervous System
Parkinson's Disease
Primary: Distribution Volume (DV) of [11C]Donepezil - BASELINE — 18.0; 22.1; 21.4; 26.6 mL
N/A N=37 Effects of Exercise on Glymphatic Functioning and Neurobehavioral Correlates in Parkinson's Disease
Parkinson's Disease and Parkinsonism · Glymphatic System
Primary: Change in Beta-Amyloid Levels — 0.016675963 SUVr
N/A N=34 DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS
Amyotrophic Lateral Sclerosis
Primary: Change in Percent of Expected Lung Force Vital Capacity — -1.25 % Expected Forced Vital Capacity
N/A N=45 Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia
Alzheimer's Disease · Frontotemporal Dementia, Behavioral Variant
Primary: Change in Clinical Disease Severity (CDR) — -0.1; 0.0; 0.0; 0.0 score on a scale